Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
June 11, 2021 Presentation

Aptose Corporate Update at EHA 2021

Aptose Corporate Update at EHA 2021: View Presentation
December 6, 2020 Presentation

Aptose Corporate Update at ASH 2020

Aptose Corporate Update at ASH 2020: View Presentation
April 27, 2020 Presentation

2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL

2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL: View Presentation
February 5, 2020 Presentation

Key Opinion Leader Symposium: CG-806 for AML

Key Opinion Leader Symposium: CG-806 for AML: View Presentation
December 7, 2019 Presentation

Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253

Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253: View Presentation
December 12, 2018 Presentation

Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers

Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers: View Presentation